KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Non-cash Items (2018 - 2021)

Aquestive Therapeutics has reported Non-cash Items over the past 4 years, most recently at $6.7 million for Q1 2021.

  • Quarterly results put Non-cash Items at $6.7 million for Q1 2021, down 22.88% from a year ago — trailing twelve months through Mar 2021 was $6.7 million (down 22.88% YoY), and the annual figure for FY2020 was $1.2 million, up 205.69%.
  • Non-cash Items for Q1 2021 was $6.7 million at Aquestive Therapeutics, up from $1.2 million in the prior quarter.
  • Over the last five years, Non-cash Items for AQST hit a ceiling of $11.4 million in Q2 2019 and a floor of $87000.0 in Q4 2018.
  • Median Non-cash Items over the past 4 years was $1.0 million (2020), compared with a mean of $3.6 million.
  • Peak annual rise in Non-cash Items hit 5854.11% in 2020, while the deepest fall reached 92.64% in 2020.
  • Aquestive Therapeutics' Non-cash Items stood at $87000.0 in 2018, then skyrocketed by 364.37% to $404000.0 in 2019, then surged by 205.69% to $1.2 million in 2020, then surged by 442.83% to $6.7 million in 2021.
  • The last three reported values for Non-cash Items were $6.7 million (Q1 2021), $1.2 million (Q4 2020), and $6.6 million (Q3 2020) per Business Quant data.